SLC6A4 and depressive symptom measurement: Depression concerns up to 2–3% of the pregnant women population and mothers are often subjected to treatment with SERT inhibitors, which may indirectly affect the foetuses via placental transfer and the infants via breastfeeding, resulting to clinical manifestations in 30% of the neonates, including breathing symptoms [55].